Desiree Soter-Pearsall, MD
Internal Medicine · Mobile, ALNPI 1649225921
Payments from drug & device makers
Across 174 payments — averaging $17.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$399
- AstraZeneca$315
- Pfizer$246
- Novo Nordisk$210
- Merck$196
- Johnson & Johnson$167
- plus $1K from 25 others
What the payments were for
- Food & beverage$2,962100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 25 | $399 |
| AstraZeneca | 19 | $315 |
| Pfizer | 15 | $246 |
| Novo Nordisk | 12 | $210 |
| Merck | 13 | $196 |
| Johnson & Johnson | 10 | $167 |
| Astellas Pharma US Inc | 9 | $148 |
| Novartis | 9 | $144 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $143 |
| Sumitomo Pharma America, Inc. | 6 | $114 |
| AbbVie(2 entities) | 7 | $107 |
| Shield Therapeutics Inc | 5 | $94 |
| Amgen | 6 | $93 |
| GSK | 4 | $82 |
| Phathom Pharmaceuticals, Inc. | 4 | $69 |
| Daiichi Sankyo Inc. | 4 | $60 |
| Boehringer Ingelheim | 4 | $59 |
| Sanofi-aventis U.S. LLC | 3 | $58 |
| Biohaven Pharmaceuticals, Inc. | 2 | $32 |
| Nevro Corp. | 1 | $31 |
| Bayer | 2 | $30 |
| Abbott | 1 | $22 |
| Corium, LLC | 1 | $19 |
| Sanofi Pasteur Inc. | 1 | $17 |
| Exact Sciences | 1 | $17 |
| Bioventus LLC | 1 | $16 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $16 |
| Bausch Health US, LLC | 1 | $15 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| Hikma Pharmaceuticals USA | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XIFAXAN$100
How this compares
$2,962 in reported general payments places this provider in the 75th percentile of 1,533 internal medicine providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 251 | $256,064 |
| TrulicityDulaglutide | 87 | $87,412 |
| EliquisApixaban | 99 | $85,548 |
| JanuviaSitagliptin Phosphate | 69 | $75,314 |
| FarxigaDapagliflozin Propanediol | 79 | $64,667 |
| MounjaroTirzepatide | 41 | $52,374 |
| JardianceEmpagliflozin | 40 | $33,503 |
| InvokanaCanagliflozin | 24 | $29,942 |
| XareltoRivaroxaban | 24 | $29,093 |
| MyrbetriqMirabegron | 42 | $24,228 |
| LinzessLinaclotide | 24 | $23,257 |
| Tresiba Flextouch U-200Insulin Degludec | 19 | $16,200 |
| EntrestoSacubitril/Valsartan | 20 | $13,785 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 11 | $12,267 |
| Tresiba Flextouch U-100Insulin Degludec | 18 | $12,112 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $210 | $256,064251 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $399 | $139,786128 claims |
| PfizerEliquis, Effexor Xr | $246 | $93,050111 claims |
| MerckJanuvia, Belsomra | $196 | $81,49183 claims |
| AstraZenecaFarxiga | $315 | $64,66779 claims |
| Johnson & JohnsonInvokana, Xarelto | $167 | $59,03548 claims |
| Boehringer IngelheimJardiance | $59 | $33,50340 claims |
| AbbVieLinzess, Synthroid | $107 | $29,12276 claims |
| Astellas Pharma US IncMyrbetriq | $148 | $24,22842 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $82 | $17,37722 claims |
| NovartisEntresto | $144 | $13,78520 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,533 internal medicine providers in Alabama.
Other internal medicine in Mobile
- Harry StuddardMobile$12.9M
- Thomas McKelveyMobile$365K
- Mary HonkanenMobile$302K
- Bobby WrightsMobile$89K
- Rahel AzizMobile$67K
- Jamie CaudillMobile$52K
- Thomas GarthMobile$48K
- Lin LiMobile$45K
- Edward CarlosMobile$26K
- Donald SandersMobile$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.